No Data
No Data
Exact Sciences Analyst Ratings
Gilead Sciences Trades in the Green for Seventh Straight Session
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Walgreens, Hims Stocks Drop as Lilly Rolls Out Cheap Weight-loss Drugs
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
KC67 Chan OP : Waiting for you at 138, you can do it